Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas
NCT02416999Unknown
- Sponsor
- Hebei Yanda Hospital
- Start
- May 2015
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of bevacizumab in glioma, sponsored by Hebei Yanda Hospital. Primary endpoints: 6-month survival rate of recurrent glioblastoma multiforme patients and 12-month survival rate of recurrent WHO-III glioma patients. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02416999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02416999.